Hints and tips:
...Five years later, the group bought CP Pharmaceuticals in Wrexham....
...Daiichi Sankyo had filed a petition contesting the sale, arguing it jeopardised the ability of the brothers to honour an arbitral award of $500m owed to them after buying Ranbaxy, a pharmaceutical company...
...The Singh brothers were once two of India’s richest billionaires, and came to international prominence in 2008 after agreeing to sell Ranbaxy, their family’s drug company, to Japan’s Daiichi Sankyo for $4.7bn...
...Fortis has been up for sale since the departure of its founders, the Singh brothers, who are facing heavy penalties relating to a previous deal to sell their drug company Ranbaxy to the Japanese company...
...The brothers came to international attention when they sold their majority stake in Ranbaxy, the pharmaceuticals company founded by Bhai Mohan Singh, their grandfather, to Daiichi Sankyo, the Japanese company...
...Shivinder and Malvinder Singh came to international attention 10 years ago when they sold their majority stake in Ranbaxy, the pharmaceuticals company founded by their grandfather, to Daiichi Sankyo, the...
...In 2013, the US FDA issued an “import alert” warning that it would seize shipments of drugs made in the then four-year-old Mohali plant owned by Ranbaxy....
...had concealed critical information relating to US regulatory investigations at the time the Japanese pharmaceuticals group bought control of its Indian rival....
...group Ranbaxy....
...But after a massive case of fraud by Ranbaxy – once one of India’s largest drug-makers – a few years ago, US regulatory authorities have been stepping up their scrutiny of Indian pharmaceutical companies...
...Dinesh Thakur was awarded nearly $48m in 2013 for exposing fraud by his former employer, drugmaker Ranbaxy, then a major exporter of generic drugs, to the US Food and Drug Administration....
...From the middle of the previous decade, inspectors and consultants had been flagging up irregularities to the pharmaceuticals company....
...Among the prominent deals that soured are Kirin’s 2011 purchase of Schincariol, Brazil’s second-largest beer group, and Daiichi Sankyo’s 2008 acquisition of Indian drugmaker Ranbaxy....
...on the pharmaceutical supply chain....
...The Indian pharmaceuticals tycoon Dilip Shangvi has vowed to do “whatever it takes” to restore US regulators’ confidence in troubled drugmaker Ranbaxy, after Sun Pharmaceutical received the go-ahead to complete...
...Such moves have fed into wider Indian tensions with the US and Europe over pharmaceuticals....
...’s biggest pharmaceutical company....
...She said Cephalon had channelled its payments to generic drugmakers including Ranbaxy, Mylan and Barr via “side deals” that included the purchase of pharmaceutical ingredients and intellectual property licences...
...AstraZeneca has nominated to its board a US scientist who has tweeted strongly critical views of the pharmaceuticals industry — including the UK group’s domestic rival GlaxoSmithKline....
...If timing is everything, then Teva, the world’s biggest maker of generic drugs, has chosen a tricky moment to try to pull off the biggest pharmaceuticals deal of the year....
...It was the first such case to come to court since a US Supreme Court ruling last year that consumers could sue drugmakers for “large and unjustified” payments that undermined competition in the pharmaceuticals...
...Ranbaxy, now in the process of being acquired by Sun Pharmaceuticals in a $3.2bn takeover, has been under scrutiny by US regulators after a whistleblower raised concerns about ethical standards, manufacturing...
...For Daiichi Sankyo, the $5bn purchase of Ranbaxy in 2008 in India ended badly with a sale this year following regulatory setbacks caused by quality issues....
...Sun announced on April 7 that it would pay up to $3.2bn for Ranbaxy, once India’s largest pharmaceutical company....
...The US Food and Drug Administration provided some help on Thursday when it withdrew its earlier support for generic Nexium from Ranbaxy, because that company’s plants were below standard....
International Edition